Effect of the long acting ARB in hypertensive patients with cerebro vasucular disease not controlled by conventional therapy.

Effect of the long acting ARB in hypertensive patients with cerebro vasucular disease not controlled by conventional therapy. - Effect of the long acting ARB in hypertensive patients with cerebro vasucular disease not controlled by conventional therapy.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009825

Enrollment

100

Registered

2013-01-21

Start date

2013-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovasucular Disease, Hypertension

Interventions

Telmisartan 80mg/day Maximum dose ARB which was Prescribed originally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatients to fulfill all the following condition can participate 1)Hypertension with cerebrovasucular disease 2)Under treatment with ARB is not telmisartan more than 3 months 3)Clinic BP:SBP>=140 and/or DBP>=90 4)40 years of age and more 5)Patients with informed consent of this study

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension 2)Severe hypertension with SBP>=180mmHg and/or DBP>=110mmHg 3)Malignant hypertension 4)Severe heart failure (NYHA III-IV) 5)Myocardial Infarction, Coronary bypass surgery, and PTCA were performed within 6 months 6)Patients contraindicated for the use of ARBs 7)Serum creatinine >=2.1mg/dL 8)Untreated hyperuricemia or serum uric acid>8mg/dL 9)Diabetes patients under insulin treatment, or HbA1c>9.0% 10)Patients with hypoglycemia 11)Patients who are inadequate by determination of physicians in charge

Design outcomes

Primary

Measure	Time frame
Central blood pressure	—

Secondary

Measure	Time frame
Clinic BP 24hr BP on ABPM IMT(Intra Media Dilation) FMD(Flow Mediated Dilation) Control rate of Clinic BP Control rate of ABPM	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026